Publications by authors named "I Sandlie"
Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive differentiator affecting dosing, frequency of administration and thereby potentially patient compliance. Here, we report on an Fc-engineered variant with three amino acid substitutions Q311R/M428E/N434W (REW), that enhances plasma half-life and mucosal distribution, as well as allows for needle-free delivery across respiratory epithelial barriers in human FcRn transgenic mice.
View Article and Find Full Text PDFArticle Synopsis
- - Immunocompromised patients struggle to build strong vaccine-induced immunity against emerging SARS-CoV-2 variants, particularly the Omicron subvariants, highlighting the need for new treatment methods.
- - Researchers have developed a long-acting viral entry-blocking molecule by fusing a modified ACE2 variant with human albumin to improve stability and binding to the virus.
- - This engineered ACE2-albumin fusion shows strong effectiveness in neutralizing SARS-CoV-2 variants and can be delivered through non-invasive nasal administration, providing a promising alternative to traditional treatments.
Article Synopsis
- Antibody-based therapeutics (ABTs) are special medicines used to treat various diseases and come in different forms, like full-length antibodies or fusions with other parts.
- These ABTs have different times in the bloodstream, which may have to do with how they interact with a specific receptor called FcRn.
- The study shows that how well these ABTs bind to FcRn affects their lifespan in the body and how they are transported inside cells, giving useful information for improving these medicines.
Introduction: The acquisition of humoral immunity in utero is essential for the fetus. The crucial protein, which is responsible for this part of immunity, is immunoglobulin-G (IgG). Immune functions of IgGs are mediated via the interaction of the crystallizable fragment (Fc) region of IgG with specific Fc γ receptors (FcγRs).
View Article and Find Full Text PDFTCR-like antibodies represent a unique type of engineered antibodies with specificity toward pHLA, a ligand normally restricted to the sensitive recognition by T cells. Here, we report a phage display-based sequential development path of such antibodies. The strategy goes from initial lead identification through in silico informed CDR engineering in combination with framework engineering for affinity and thermostability optimization, respectively.
View Article and Find Full Text PDF